141 related articles for article (PubMed ID: 36586160)
1. Aberrant NAD synthetic flux in podocytes under diabetic conditions and effects of indoleamine 2,3-dioxygenase on promoting de novo NAD synthesis.
Zhang Y; Zhao X; Li C; Yang Y; Li L; Chen Y; Shi Q; Li Z; Wu Y; Zhang L; Li R; Si M; Liang X; Chen Y
Biochem Biophys Res Commun; 2023 Feb; 643():61-68. PubMed ID: 36586160
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of indoleamine 2,3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels.
Grant R; Kapoor V
Biochem Pharmacol; 2003 Sep; 66(6):1033-6. PubMed ID: 12963490
[TBL] [Abstract][Full Text] [Related]
3. PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease.
Zhang Z; Liang W; Luo Q; Hu H; Yang K; Hu J; Chen Z; Zhu J; Feng J; Zhu Z; Chi Q; Ding G
Front Endocrinol (Lausanne); 2021; 12():797025. PubMed ID: 35095764
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the nexus of NAD+ metabolism and diabetic kidney disease: insights from murine models and human data.
Yang S; Gong W; Wang Y; Hao C; Guan Y
Front Endocrinol (Lausanne); 2024; 15():1384953. PubMed ID: 38836233
[TBL] [Abstract][Full Text] [Related]
5. Kynurenine 3-monooxygenase limits de novo NAD
Zhai Y; Chavez JA; D'Aquino KE; Meng R; Nawrocki AR; Pocai A; Wang L; Ma LJ
Am J Physiol Cell Physiol; 2024 May; 326(5):C1423-C1436. PubMed ID: 38497113
[TBL] [Abstract][Full Text] [Related]
6. Evolutionary Views of Tuberculosis: Indoleamine 2,3-Dioxygenase Catalyzed Nicotinamide Synthesis Reflects Shifts in Macrophage Metabolism: Indoleamine 2,3-Dioxygenase Reflects Altered Macrophage Metabolism During Tuberculosis Pathogenesis.
Suchard MS; Adu-Gyamfi CG; Cumming BM; Savulescu DM
Bioessays; 2020 May; 42(5):e1900220. PubMed ID: 32301149
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease.
Penberthy WT
Curr Drug Metab; 2007 Apr; 8(3):245-66. PubMed ID: 17430113
[TBL] [Abstract][Full Text] [Related]
8. STIM promotes the epithelial-mesenchymal transition of podocytes through regulation of FcγRII activity in diabetic nephropathy.
Jin J; Ye M; Hu K; Gong J; He Q
Histol Histopathol; 2019 Jun; 34(6):671-682. PubMed ID: 30475382
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
10. Macrophage de novo NAD
Minhas PS; Liu L; Moon PK; Joshi AU; Dove C; Mhatre S; Contrepois K; Wang Q; Lee BA; Coronado M; Bernstein D; Snyder MP; Migaud M; Majeti R; Mochly-Rosen D; Rabinowitz JD; Andreasson KI
Nat Immunol; 2019 Jan; 20(1):50-63. PubMed ID: 30478397
[TBL] [Abstract][Full Text] [Related]
11. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
[TBL] [Abstract][Full Text] [Related]
12. Dihydroxyacetone phosphate accumulation leads to podocyte pyroptosis in diabetic kidney disease.
Zhang Z; Hu H; Luo Q; Yang K; Zou Z; Shi M; Liang W
J Cell Mol Med; 2024 Feb; 28(3):e18073. PubMed ID: 38063077
[TBL] [Abstract][Full Text] [Related]
13. PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy.
Lin Y; Shao Z; Zhao M; Li J; Xu X
Biochem Biophys Res Commun; 2021 Apr; 550():62-69. PubMed ID: 33684622
[TBL] [Abstract][Full Text] [Related]
14. p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K/Akt/mTOR pathway.
Zheng D; Tao M; Liang X; Li Y; Jin J; He Q
Histol Histopathol; 2020 Apr; 35(4):405-415. PubMed ID: 31650524
[TBL] [Abstract][Full Text] [Related]
15. Tripterygium glycoside suppresses epithelial‑to‑mesenchymal transition of diabetic kidney disease podocytes by targeting autophagy through the mTOR/Twist1 pathway.
Tao M; Zheng D; Liang X; Wu D; Hu K; Jin J; He Q
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34165172
[TBL] [Abstract][Full Text] [Related]
16. IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress.
Grant RS; Naif H; Espinosa M; Kapoor V
Redox Rep; 2000; 5(2-3):101-4. PubMed ID: 10939283
[TBL] [Abstract][Full Text] [Related]
17. Molecular evolution of bacterial indoleamine 2,3-dioxygenase.
Yuasa HJ; Ushigoe A; Ball HJ
Gene; 2011 Oct; 485(1):22-31. PubMed ID: 21689736
[TBL] [Abstract][Full Text] [Related]
18. Elevated Expression of indoleamine 2,3-dioxygenase (IDO) and accumulation of kynurenic acid in the pathogenesis of STZ-induced diabetic cataract in Wistar rats.
Kanth VR; Lavanya K; Srinivas J; Raju TN
Curr Eye Res; 2009 Apr; 34(4):274-81. PubMed ID: 19373575
[TBL] [Abstract][Full Text] [Related]
19. Growth associated protein 43 deficiency promotes podocyte injury by activating the calmodulin/calcineurin pathway under hyperglycemia.
Yang Y; Shi W; Li C; Li L; Li J; Chen Y; Shi Q; Xie Z; Wang M; Zhang H; Zhao X; Chen Y; Li R; Liu S; Ye Z; Zhang L; Liang X
Biochem Biophys Res Commun; 2023 May; 656():104-114. PubMed ID: 36963347
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation.
Eleftheriadis T; Pissas G; Antoniadi G; Spanoulis A; Liakopoulos V; Stefanidis I
Int Immunol; 2014 Dec; 26(12):673-84. PubMed ID: 25064493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
